JASPER THERAPEUTICS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
JASPER THERAPEUTICS, INC. (JSPR) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $1.63 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-05.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2024-03-05
- JASPER THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2023 was $1.63M, a 11.28% decline from fiscal 2022.
- JASPER THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2022 was $1.83M, a 67.58% increase from fiscal 2021.
- JASPER THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2021 was $1.09M, a 267.45% increase from fiscal 2020.
- JASPER THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2020 was $298.00K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month |
|---|---|
| 2023-12-31 | $1.63M 10-K · filed 2024-03-05 |
| 2022-12-31 | $1.83M 10-K · filed 2024-03-05 |
| 2021-12-31 | $1.09M 10-K · filed 2023-03-08 |
| 2020-12-31 | $298.00K 10-K · filed 2022-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |